期刊文献+

羟基喜树碱、5-氟尿嘧啶、阿霉素联合化疗治疗胃癌的临床观察 被引量:9

HYDROXYL-CAMPTOTHECIN FLUOROURACIL AND ADRIAMYCIN COMBINATION CHEMOTHERAPY IN GASTRIC CANCER:A CLINICAL REPORT OF 42 CASES
下载PDF
导出
摘要 目的观察羟基喜树碱(HCPT),5一氟尿嘧啶(5-FU)和阿霉素(ADM)联合化疗治疗胃癌的疗效和耐受性。方法42例胃癌患者接受HCPT10mg静滴,第1~5天;5-FU750mg,静滴第1~3天;ADM50mg静滴第1天的联合化疗。每3周为一疗程。结果可评价疗效患者24例,总缓解率41.7%(10/24),完全缓解率(CR)8.3%(3/24),部分缓解率(PR)33.3%(8/24)。可评价毒性患者42例,白细胞减少发生率为88%(3~4度仅4.7%),血红蛋白减少和血小板减少分别为19%和28.5%。脱发为100%。其他毒副反应少见。结论以HCPT为主组成的FAHCPT方案治疗胃癌有一定疗效,且毒性可耐受。 To assess the antitumor efficacy of and tolerance to the combination of Hydroxyl-camptothecin(HCPT). Fluorouracil (5-FU) and adriamycin (ADM) in gastric cancer. METHODS Between March 1995 andAugust 1996, forty-two patients with gastric cancer received HCPT 10 mg/body/d for 5 consecutive days by intravenous infusion (IV). 5-FU 750 mg/body/d for 3 consecutive days as IV and ADM 50 mg/body on day 1 Ⅳ ev every 3 weeks. RESULTS Twenty-four patients were evaluable for efficacy. The overall response rate was 41. 7%(10/24) and the complete response rate was 8. 3% (2/24). the partial response rate 33. 3% (8/24). 42 patientswere evaluable for toxicity. Leukopenia was observed in 88% of patients, but grade 3 and 4 toxicity in only 4. 7% ofpatients. Anemia and thrombocytopenia were observed in 19% and 21. 4% of patients, respectively. alopecia in100%, which was related to the use of ADM. other side effects were uncommon. CONCLUSION This study showsthat the combination of HCPT, 5-FU and ADM is an active and tolerable regimen for treatment of gastric cancer.
机构地区 浙江省肿瘤医院
出处 《中国癌症杂志》 CAS CSCD 1998年第3期190-192,共3页 China Oncology
关键词 胃癌 羟基喜树碱 药物疗法 5-氟尿嘧啶 阿霉素 Gastric cancer Hydroxyl-camptothecin Drug therapy
  • 相关文献

参考文献9

二级参考文献1

  • 1凌义和,俞伟娟,胥彬.10-羟基喜树碱对小鼠肝癌细胞转运嘧啶核苷的影响[J]Acta Biochimica et Biophysica Sinica,1983(06). 被引量:1

共引文献185

同被引文献22

  • 1李国栋.拓朴异构酶特性与肿瘤细胞的耐药性[J].河南肿瘤学杂志,1996,9(4):317-319. 被引量:72
  • 2Artur P, Andre T, Tigrud J, et al. Oxaliplatin (OXA),5-fluorouracil (Fu) and folinic acid (FA) (FOLFOX6)in advanced/metastatic gastric carcinoma (A/MGC) patients(Pts): final resalts of a multicenter phase Ⅱ study [J]. Proc Am Soc Clin Oncol, 2001,20:164a 被引量:1
  • 3Mauer AM, Kraut EH, Rudin CM, et al. Phase Ⅱ study of oxaliplatin (OX), fluorouracil (FU) and leucovorin (LV) in metastatic carcinoma of the esophagus/gastric cardia [J]. Proc Am Soc Clin Oncol, 2002, 21:139a (abstr 554) 被引量:1
  • 4Chao Y, Yeh KH, Chang CJ, et al. A phase Ⅱ study of oxaliplatin and weekly 24-hour infusion of high dose 5--fluorouracil and leucovorin(HDFL)in the first-line treatment of inoperable, locally advanced or recurrent/metastatic gstric cancers [J]. Proc Am S 被引量:1
  • 5Louvet C, Andre T, Tigaud JM, et al. Phase Ⅱ study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients [J]. J Clin Oncol, 2002, 20 (23):4543 -4548 被引量:1
  • 6Bang YJ, Kang YK, Kang WK, et al. Phase Ⅱ study of oxaliplatin,5-fluorourcil and folinic acid in recuyyemt or metastatic gastric cancer[J]. Proc Am Soc Clin Oncol, 2002, 21:109b, (abstr 2249) 被引量:1
  • 7BANG Y J;Kang YK;Kang WK.Phase Ⅱ study of oxaliplatin,5-fiuorourcil and folinic acidin recuyyent or metastatic gastric cancer,2002. 被引量:1
  • 8Ghao Y;Ych KH;Chang C J.A phase Ⅱ study of oxaliplatin and weekly 24-hour inthsion of high dose 5-tluorouracil and leucovorin (HDFL) in the first-line treatment of inoperable, locallyadvanced or recurrent/metastatic gstric cancers,2002. 被引量:1
  • 9Mauer A M;Kraut EH;Rudin GM.Phase Ⅱ study of oxaliplatin (OX), fiuorouracil (FU)and leucovorin (LV) in metastatic carcinoma of the esophagus/gastric cardia~,2002. 被引量:1
  • 10Artru P;Andre T;Tigrud .J.Oxaliplatin (OXA),5-[luo-rouracil (Fu) and folinic acid (FA) (FOLFOX6)in advanced/metastatic gastric carcinoma (A/MGG) patients(Pts): final resahs of amulticenter phase Ⅱ study,2001(354). 被引量:1

引证文献9

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部